Methods of using regenerative cells in the treatment of stroke and related diseases and disorders
View Patent ↗Cells present in adipose tissue are used to stroke and stroke related diseases and disorders in a patient. Methods of treating patients include processing adipose tissue to deliver a concentrated amount of regenerative cells obtained from the adipose tissue to a patient. The methods may be practiced in a closed system so that the regenerative cells are not exposed to an external environment prior to being administered to a patient. Accordingly, in a preferred method, cells present in adipose tissue are placed directly into a recipient along with such additives necessary to promote, engender or support a therapeutic benefit.
1. A method of alleviating at least one adverse effect of stroke in a patient in need of an increased blood flow to an ischemic region comprising:
identifying a patient in need of an increased blood flow to an ischemic region, wherein said patient has at least one symptom of stroke; and
providing to said patient an amount of an autologous, concentrated, heterogeneous population of cells comprising adipose-derived stem cells and progenitor cells sufficient to increase blood flow to said ischemic region and alleviate said symptom of stroke wherein said concentrated, heterogeneous population of cells comprising adipose-derived stem cells and progenitor cells has not been cultured.
2. The method of claim 1 , wherein the autologous, concentrated, heterogeneous population of cells comprising adipose-derived stem cells is provided by intravenous infusion.
3. The method of claim 1 , wherein the autologous, concentrated, heterogeneous population of cells comprising adipose-derived stem cells provided is within a range of about 1×10 5 cells/ml to about 1×10 7 cells/ml.
4. The method of claim 1 , further comprising performing a neurologic examination of said patient.
5. The method of claim 1 , further comprising performing an MRI on said patient.
6. The method of claim 1 , further comprising performing doppler imaging on said patient.
7. The method of claim 1 , wherein said stroke is an ischemic stroke.
8. The method of claim 1 , wherein said autologous concentrated, heterogeneous population of cells comprising adipose-derived stem cells and progenitor cells further comprises an additive selected from the group consisting of bFGF, HGF, IL-6, and IL-13.
9. The method of claim 1 , wherein said autologous concentrated, heterogeneous population of cells comprising adipose-derived stem cells and progenitor cells further comprises a cellular re-aggregation inhibitor or a disaggregation agent.
10. The method of claim 1 , wherein the autologous concentrated, heterogeneous population of cells comprising adipose-derived stem cells and progenitor cells are provided via a subcutaneous, intra-carotid artery, intra-arterial, intrathecal or intra-parenchymal delivery route.
11. The method of claim 1 , wherein the autologous, concentrated, heterogeneous population of cells comprising adipose-derived stem cells and progenitor cells are administered in a bolus.
12. The method of claim 1 , wherein the autologous, concentrated, heterogeneous population of cells comprising adipose-derived stem cells and progenitor cells are administered in multiple doses.
13. The method of claim 1 , wherein the autologous, concentrated, heterogeneous population of cells comprising adipose-derived stem cells and progenitor cells are separated from mature adipocytes and connective tissue.
14. The method of claim 1 , wherein the autologous, concentrated, heterogeneous population of cells comprising adipose-derived stem cells and progenitor cells further comprises a neurogenic factor.
15. The method of claim 1 , wherein the autologous, concentrated, heterogeneous population of cells comprising adipose-derived stem cells and progenitor cells is cryopreserved.